Study type: Human research · Status: Citation identity verified

Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER.

Genetics in medicine : official journal of the American College of Medical Genetics · 2024

Study scale: Not reported

Citation only: Open source record

Product or molecular entity relationships

SS-31: Catalog source association. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.

Plain-language verified summary

Question

Not reported in the reviewed source.

Methods

Not reported in the reviewed source.

Scale or participants

Not reported in the reviewed source.

Key findings

Not reported in the reviewed source.

Limitations and uncertainty

Not reported in the reviewed source.

Citation identity verified. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.